Executive Summary

With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing 
deals by next year. Amid growing global interest in RNA interference therapeutics and using newly licensed in NAcetylgalactosamine (GalNAc) conjugation technology, OliX Pharmaceuticals, Inc.
is emerging as a potential dark horse for partnerships in the field.  

With the biotech’s core therapeutic technology, asymmetric siRNA (asiRNA), OliX says it has plenty to look forward to in the coming months. It is starting or progressing clinical trials for various

pipeline assets in global markets and further expanding its R&D portfolio. Global pharma firms are more keenly eyeing the company after it licensed in the GalNAc conjugation technology. “By 2021, we aim to grow our partnerships and R&D efforts to expand the company pipeline and develop potential RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Multiple global pharma-ceutical and biotech companies are now in contact for expanded collaborations.” OliX founder and CEO Dong Ki Lee said in an email interview with Scrip.

-R&D Progress Includes COVID-19 Pipeline

-GalNAc Technology Piques Pharma Interest 

-US To Lead Globalization Effort 

*Attached: OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform